NAMS Earnings

Quarterly EPS
$-0.18
Q3 2024
$-0.93
Q4 2024
$-0.34
Q1 2025
$-0.15
Q2 2025
$-0.61
Q3 2025
$-0.62
Q4 2025
$-0.40
Q1 2026
$-0.52
Q2 2026
Latest Revenue3.7M
Latest Net Income-64135000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.523.7M-64135000-80.7%-246.7%
Q1 2026-$0.403.0M-48441000+2.1%-17.6%
Q4 2025-$0.6232.0K-74923000-99.7%+33.3%
Q3 2025-$0.61348.0K-72005000-98.8%-238.9%
Q2 2025-$0.1519.1M-17364000+740.1%+63.4%
Q1 2025-$0.343.0M-39527000+112.6%+67.9%
Q4 2024-$0.9312.8M-92177000+1,490.5%-55.0%
Q3 2024-$0.1829.1M-16647000+889.8%+68.4%
Q2 2024-$0.412.3M-39007000
Q1 2024-$1.061.4M-93767000
Q4 2023-$0.60803.0K-49495000
Q3 2023-$0.572.9M-47133000
NewAmsterdam Pharma Company N.V. (NAMS) — Earnings